Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients

Berger, Eloïse; Delpierre, Cyrille; Despas, Fabien; Bertoli, Sarah; Bérard, Emilie; Bombarde, Oriane; Bories, Pierre; Sarry, Audrey; Laurent, Guy; Récher, Christian; Lamy, Sébastien

doi:10.1186/s12885-019-6093-3

Table 3 Step 1. Survival in association with patients’ SEP adjusted for treatment, patients’ and disease characteristics

From: Are social inequalities in acute myeloid leukemia survival explained by differences in treatment utilization? Results from a French longitudinal observational study among older patients

Main components		Model 1.0 (M1.0)			Model 1.1		Model 1.2		Model 1.3		Model 1.4		Model 1.5		Model 1.6		M 1.7
		Model 1.0 (M1.0)			M1.0 + perf. Status		M1.0 + AML ont		M1.0 + WBC.		M1.0 + cyto. Progn.		M1.0 + treatment		All but treatment		Fully adjusted
		HR	[95% CI]		HR	[95% CI]	HR	[95% CI]	HR	[95% CI]	HR	[95% CI]	HR	[95% CI]	HR	[95% CI]	HR	[95% CI]
Age		1.04	[1.03; 1.05]		1.03	[1.02; 1.05]	1.04	[1.03; 1.05]	1.04	[1.03; 1.05]	1.04	[1.02; 1.05]	1.01	[1.00; 1.03]	1.03	[1.02; 1.05]	1.02	[1.00; 1.03]
Sex	Men	ref			ref		ref		ref				ref		Ref		ref
Sex	Women	0.88	[0.73; 1.07]		0.86	[0.71; 1.04]	0.87	[0.72; 1.05]	0.89	[0.74; 1.08]	0.84	[0.69; 1.01]	0.87	[0.72; 1.05]	0.81	[0.67; 0.98]	0.82	[0.68; 1.00]
Patients’ SEP (quintile of deprivation score)	Q1 – least	ref			Ref		Ref		Ref				Ref		ref		Ref
	Q2	1.14	[0.85; 1.53]		1.11	[0.83; 1.50]	1.08	[0.80; 1.45]	1.17	[0.87; 1.35]	1.06	[0.79; 1.42]	1	[0.84; 1.50]	1.01	[0.75; 1.37]	0.96	[0.71; 1.29]
	Q3	0.89	[0.67; 1.18]		0.85	[0.64; 1.13]	0.83	[0.62; 1.11]	0.88	[0.66; 1.17]	0.89	[0.67; 1.18]	0.84	[0.69; 1.22]	0.80	[0.60; 1.07]	0.78	[0.58; 1.04]
	Q4	1.07	[0.82;	1.40]	1.02	[0.78; 1.33]	1.03	[0.79; 1.35]	1.07	[0.82; 1.40]	1.06	[0.81; 1.38]	1	[0.82; 1.40]	0.99	[0.75; 1.30]	0.94	[0.71; 1.24]
	Q5 – most	1.39	[1.04; 1.87]		1.37	[1.02; 1.84]	1.31	[0.97; 1.76]	1.47	[1.10; 1.97]	1.30	[0.97; 1.75]	1.35	[1.12; 2.01]	1.28	[0.95; 1.73]	1.29	[0.95; 1.74]
Charlson comorbidity index	0	ref			ref		ref		ref				ref		ref		ref
	1	1.1	[0.86; 1.41]		1.02	[0.80; 1.31]	1.08	[0.85; 1.38]	1.15	[0.90; 1.47]	1.09	[0.86; 1.40]	1.01	[0.79; 1.29]	1.07	[0.83; 1.37]	1.00	[0.78; 1.28]
	2+	1.29	[1.01; 1.66]		1.18	[0.92; 1.52]	1.21	[0.94; 1.56]	1.3	[1.01; 1.66]	1.35	[1.06; 1.73]	1.13	[0.88; 1.45]	1.19	[0.92; 1.54]	1.08	[0.83; 1.41]
	Undefined	2.1	[1.60; 2.76]		1.89	[1.39; 2.56]	1.88	[1.40; 2.53]	2.06	[1.56; 2.73]	1.97	[1.49; 2.61]	1.29	[0.96; 1.74]	1.66	[1.20; 2.31]	1.25	[0.89; 1.75]
Performance status	0/1				ref										Ref		ref
	2				1.51	[1.16; 1.97]									1.49	[1.15; 1.95]	1.50	[1.15; 1.95]
	3/4				2.36	[1.70; 3.28]									1.90	[1.34; 2.68]	1.72	[1.22; 2.42]
	Undefined				1.75	[1.24; 2.48]									1.52	[1.04; 2.20]	1.29	[0.88; 1.88]
AML ontogeny	AML de novo						ref								Ref		ref
	Secondary AML (post treatment / MDS)						1.25	[1.03; 1.52]							1.21	[0.99; 1.48]	1.12	[0.91; 1.38]
	Undefined						1.56	[0.90; 2.72]							1.60	[0.90; 2.83]	1.52	[0.86; 2.70]
White blood cell (WBC) counts (tercile)	Tercile 1 – low								ref								Ref
	Terticle 2 – intermediate								1.42	[1.10; 1.83]					1.38	[1.06; 1.79]	1.34	[1.04; 1.74]
	Terticle 3 – high								2.24	[1.66; 3.01]					2.16	[1.59; 2.93]	2.36	[1.74; 3.20]
	Undefined								2.9	[1.50; 5.60]					2.28	[1.14; 4.56]	2.10	[1.05; 4.21]
Cytogenetic prognosis	Favorable/Intermediate
	Unfavorable										2.00	[1.64; 2.43]			2.01	[1.64; 2.46]	1.72	[1.38; 2.13]
	Undefinable										1.99	[1.34; 2.96]			1.88	[1.24; 2.86]	1.44	[0.95; 2.18]
Treatment	Intensive chemotherapy												ref
	Low intensive therapy												1.53	[1.19; 1.96]			1.36	[1.01; 1.82]
	Best supportive care												4.11	[2.93; 5.77]			3.24	[2.21; 4.76]
Time varying component
Time * Performance status					0.9998 [0.9997;0.9999]										0.9999 [0.9998; 1.0000]		0.9999 [0.9998; 1.0000]
Time * White blood cell counts									0.9993 [0.9990; 0.9996]						0.9993 [0.9989; 0.9996]		0.9992 [0.9990; 0.9996]

Adjusted hazard ratios [95% Confidence Intervals] of overall mortality from Adjusted Cox proportional hazards model with time dependent variables (n = 592)

Back to article page

ISSN: 1471-2407

Contact us

Submission enquiries: bmccancer@biomedcentral.com
General enquiries: ORSupport@springernature.com

BMC Cancer

Contact us